Results 51 to 60 of about 7,206 (161)

Immune microenvironment and immunotherapy for chordoma

Frontiers in Oncology
Chordoma, as a rare, low-grade malignant tumor that tends to occur in the midline of the body, grows slowly but often severely invades surrounding tissues and bones.
Yujia Chen, Hongwei Zhang
doaj   +1 more source

Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT

Cancer Cell International, 2019
Background Tripartite motif-containing protein 11 (TRIM11), a member of RING family of E3 ubiquitin ligases, is identified as an oncogene in certain human tumors. However, the detailed biological function of TRIM11 in chordoma is still unclear.
Bin Wang, Gang Wang, Qingfeng Wang, Ziqiang Zhu, Yunqing Wang, Kangwu Chen, Huilin Yang   +6 more
doaj   +1 more source

Molecular features and vulnerabilities of recurrent chordomas

Journal of Experimental & Clinical Cancer Research, 2021
Background Tumor recurrence is one of the major challenges in clinical management of chordoma. Despite R0-resection, approximately 50% of chordomas recur within ten years after initial surgery.
Carolin Seeling, André Lechel, Michael Svinarenko, Peter Möller, Thomas F. E. Barth, Kevin Mellert   +5 more
doaj   +1 more source

Chordoma.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974
The history, origin, pathology, diagnosis, treatment and prognosis of chordoma involving the axial skeleton are reviewed, and the clinical histories of 3 cases of chordoma are given, noting some remarkable features, along with one case misdiagnosed as chordoma on the radiological appearance of the sacrum and treated as such, which later proved to be a ...
Fichardt, T., de Villiers, P.C.
openaire   +3 more sources

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 1, January 2026.
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li, Yuezhou Wu, Zhu'anzhen Zheng, Fengjin Zhou, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Microstructural profiling and habitat analysis to characterize treatment outcome patterns in Sacral Chordomas treated with carbon ions

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background Sacral chordoma (SC) is a rare and locally aggressive tumor, characterized by a high risk of local recurrence (LR). Advanced imaging biomarkers capturing tumor heterogeneity and treatment response may help refine patient stratification and improve outcomes.
Letizia Morelli, Giovanni Parrella, Marco Rotondi, Silvia Molinelli, Giuseppe Magro, Sara Imparato, Agnieszka Chalaszczyk, Maria Rosaria Fiore, Chiara Paganelli, Ester Orlandi, Guido Baroni   +10 more
wiley   +1 more source

Prognostic factors and overall survival in pelvic Ewing's sarcoma and chordoma: A comparative SEER database analysis

Heliyon
Background: This study aimed to develop and validate nomograms to predict overall survival (OS) for pelvic Ewing's sarcoma (EWS) and chordoma, identify prognostic factors, and compare outcomes between the two conditions.
Wanyun Tang, Runzhuo Li, Xiaoying Lai, Xiaohan Yu, Renjian He   +4 more
doaj   +1 more source

Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background Although pediatric, adolescent and young adults (AYA) patients are known to be eligible for proton therapy, the presence of high linear energy transfer (LET) in critical structures, such as the brainstem, could lead to an increased risk of toxicity.
Alfredo Mirandola, Matteo Bagnalasta, Giuseppe Magro, Alessia Bazani, Silvia Molinelli, Vittoria Pavanello, Eleonora Rossi, Stefania Russo, Luca Trombetta, Alessandro Vai, Francesca Colombo, Ester Orlandi, Mario Ciocca, Sabina Vennarini   +13 more
wiley   +1 more source

N6‐methyladenosine‐modified circTEAD1 stabilizes Yap1 mRNA to promote chordoma tumorigenesis

Clinical and Translational Medicine
Background Chordoma, a rare bone tumour with aggressive local invasion and high recurrence rate with limited understanding of its molecular mechanisms. Circular RNAs (circRNAs) have been extensively implicated in tumorigenesis, yet their involvement in ...
Hanwen Li, Yingchuang Tang, Xingbang Ruan, Junxin Zhang, Hao Liu, Shiyu Yu, Hao Chen, Huilin Yang, Kai Zhang, Kangwu Chen   +9 more
doaj   +1 more source